NYSE:QGEN Qiagen (QGEN) Stock Forecast, Price & News $44.92 -0.91 (-1.99%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$44.87▼$45.4250-Day Range$43.93▼$46.7652-Week Range$40.38▼$51.18Volume954,718 shsAverage Volume854,075 shsMarket Capitalization$10.23 billionP/E Ratio29.17Dividend YieldN/APrice Target$54.87 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Qiagen MarketRank™ ForecastAnalyst RatingHold2.40 Rating ScoreUpside/Downside22.1% Upside$54.87 Price TargetShort InterestHealthy1.27% of Float Sold ShortDividend StrengthN/ASustainability-0.83Upright™ Environmental ScoreNews Sentiment0.37Based on 8 Articles This WeekInsider TradingN/AProj. Earnings Growth7.55%From $2.12 to $2.28 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.49 out of 5 starsMedical Sector128th out of 981 stocksBiological Products, Except Diagnostic Industry20th out of 162 stocks 2.2 Analyst's Opinion Consensus RatingQiagen has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $54.87, Qiagen has a forecasted upside of 22.1% from its current price of $44.92.Amount of Analyst CoverageQiagen has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.27% of the float of Qiagen has been sold short.Short Interest Ratio / Days to CoverQiagen has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Qiagen has recently decreased by 8.95%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldQiagen does not currently pay a dividend.Dividend GrowthQiagen does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreQiagen has received a 69.71% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Pharmacovigilance services", "Clinical research services", and "Biochemical assay kits" products. See details.Environmental SustainabilityThe Environmental Impact score for Qiagen is -0.83. Previous Next 3.0 News and Social Media Coverage News SentimentQiagen has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Qiagen this week, compared to 5 articles on an average week.Search Interest1 people have searched for QGEN on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Qiagen to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Qiagen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.00% of the stock of Qiagen is held by insiders.Percentage Held by Institutions58.62% of the stock of Qiagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Qiagen are expected to grow by 7.55% in the coming year, from $2.12 to $2.28 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Qiagen is 29.17, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 142.98.Price to Earnings Ratio vs. SectorThe P/E ratio of Qiagen is 29.17, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 129.47.Price to Earnings Growth RatioQiagen has a PEG Ratio of 8.36. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioQiagen has a P/B Ratio of 2.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Qiagen (NYSE:QGEN) StockQIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.Read More Receive QGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Qiagen and its competitors with MarketBeat's FREE daily newsletter. Email Address QGEN Stock News HeadlinesJune 7, 2023 | markets.businessinsider.comQiagen (QGEN) Receives a Hold from JefferiesJune 7, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Qiagen (QGEN), AmerisourceBergen (ABC) and Doximity (DOCS)June 8, 2023 | Edge On The Street (Ad)The Real Problem With "Made in America" LithiumPoliticians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple. June 7, 2023 | markets.businessinsider.comQiagen (QGEN) Receives a Hold from UBSMay 27, 2023 | americanbankingnews.comQiagen (NYSE:QGEN) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 26, 2023 | entrepreneur.com3 Medical Stocks Rated BUYMay 26, 2023 | markets.businessinsider.comKepler Capital Keeps Their Hold Rating on Qiagen (QGEN)May 23, 2023 | finance.yahoo.comQIAGEN (QGEN) Expands Enzyme Offering to Aid LaboratoryJune 8, 2023 | Edge On The Street (Ad)New "Mined in America" Lithium Opportunities?The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.May 23, 2023 | americanbankingnews.comQiagen (NYSE:QGEN) Upgraded by Morgan Stanley to OverweightMay 21, 2023 | americanbankingnews.comQiagen (NYSE:QGEN) Research Coverage Started at StockNews.comMay 21, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Qiagen (NASDAQ:QGEN)May 16, 2023 | seekingalpha.comQGEN Qiagen N.V.May 13, 2023 | morningstar.comQiagen NV QGEN Stock QuoteMay 9, 2023 | americanbankingnews.comBrokers Offer Predictions for Qiagen's Q1 2024 Earnings (NYSE:QGEN)May 7, 2023 | americanbankingnews.comQiagen (NYSE:QGEN) Given New $50.00 Price Target at UBS GroupMay 4, 2023 | seekingalpha.comQiagen N.V. 2023 Q1 - Results - Earnings Call PresentationMay 4, 2023 | americanbankingnews.comQiagen (NYSE:QGEN) Releases Earnings Results, Beats Expectations By $0.04 EPSMay 3, 2023 | finance.yahoo.comQiagen (QGEN) Q1 Earnings Beat EstimatesMay 3, 2023 | finance.yahoo.comQIAGEN welcomes U.S. Preventive Services Task Force reaffirmation for latent TB screening in populations at increased riskApril 30, 2023 | americanbankingnews.comQiagen (NYSE:QGEN) Receives $55.53 Average Price Target from BrokeragesApril 28, 2023 | finance.yahoo.comIs Weakness In Qiagen N.V. (NYSE:QGEN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?April 22, 2023 | americanbankingnews.com (QGEN) & Its Rivals Head-To-Head ReviewApril 20, 2023 | finance.yahoo.comQIAGEN announces expansion of Supervisory BoardApril 18, 2023 | finance.yahoo.comEarnings Preview: Qiagen (QGEN) Q1 Earnings Expected to DeclineApril 15, 2023 | finanznachrichten.deQIAGEN N.V.: QIAGEN präsentiert neueste Technologien für die Krebsforschung beim Jahrestreffen der American Association for Cancer ResearchApril 14, 2023 | finance.yahoo.comQIAGEN showcases latest technologies to advance cancer research at AACR Annual Meeting 2023See More Headlines QGEN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart QGEN Company Calendar Last Earnings5/03/2023Today6/07/2023Next Earnings (Estimated)7/25/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNYSE:QGEN CUSIPN/A CIK1015820 Webwww.qiagen.com Phone(177) 355-6600Fax31-77-355-6658Employees6,178Year FoundedN/APrice Target and Rating Average Stock Price Forecast$54.87 High Stock Price Forecast$60.00 Low Stock Price Forecast$50.00 Forecasted Upside/Downside+22.1%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$1.54 Trailing P/E Ratio29.17 Forward P/E Ratio21.19 P/E Growth8.38Net Income$423.21 million Net Margins17.66% Pretax Margin21.31% Return on Equity14.08% Return on Assets7.61% Debt Debt-to-Equity Ratio0.42 Current Ratio2.53 Quick Ratio2.10 Sales & Book Value Annual Sales$2.14 billion Price / Sales4.78 Cash Flow$3.39 per share Price / Cash Flow13.24 Book Value$15.22 per share Price / Book2.95Miscellaneous Outstanding Shares227,720,000Free Float207,222,000Market Cap$10.23 billion OptionableOptionable Beta0.38 Key ExecutivesThierry BernardChief Executive Officer & Managing DirectorAntonio SantosSenior Vice President & Head-Global OperationsRoland SackersChief Financial Officer & Managing DirectorPhilipp von HugoVP, Head-Global Legal Affairs & ComplianceLezette YoungManager-Compliance & LegalKey CompetitorsRepligenNASDAQ:RGENNeurocrine BiosciencesNASDAQ:NBIXBio-TechneNASDAQ:TECHExelixisNASDAQ:EXELCRISPR TherapeuticsNASDAQ:CRSPView All CompetitorsInstitutional OwnershipAlterna Wealth Management Inc.Bought 4,407 shares on 5/26/2023Ownership: 0.002%Toroso Investments LLCSold 878 shares on 5/23/2023Ownership: 0.005%Ameriprise Financial Inc.Sold 5,782 shares on 5/22/2023Ownership: 0.003%JPMorgan Chase & Co.Bought 239,204 shares on 5/18/2023Ownership: 0.662%New York State Common Retirement FundSold 10,944 shares on 5/18/2023Ownership: 0.115%View All Institutional Transactions QGEN Stock - Frequently Asked Questions Should I buy or sell Qiagen stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" QGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in QGEN, but not buy additional shares or sell existing shares. View QGEN analyst ratings or view top-rated stocks. What is Qiagen's stock price forecast for 2023? 5 equities research analysts have issued twelve-month price objectives for Qiagen's stock. Their QGEN share price forecasts range from $50.00 to $60.00. On average, they predict the company's share price to reach $54.87 in the next year. This suggests a possible upside of 22.1% from the stock's current price. View analysts price targets for QGEN or view top-rated stocks among Wall Street analysts. How have QGEN shares performed in 2023? Qiagen's stock was trading at $49.87 on January 1st, 2023. Since then, QGEN shares have decreased by 9.9% and is now trading at $44.92. View the best growth stocks for 2023 here. Are investors shorting Qiagen? Qiagen saw a decline in short interest during the month of April. As of April 30th, there was short interest totaling 3,130,000 shares, a decline of 20.6% from the April 15th total of 3,940,000 shares. Based on an average daily volume of 779,200 shares, the days-to-cover ratio is presently 4.0 days. Approximately 1.4% of the shares of the company are short sold. View Qiagen's Short Interest. When is Qiagen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 25th 2023. View our QGEN earnings forecast. How were Qiagen's earnings last quarter? Qiagen (NYSE:QGEN) released its quarterly earnings results on Wednesday, May, 3rd. The company reported $0.51 earnings per share for the quarter, beating analysts' consensus estimates of $0.47 by $0.04. The company had revenue of $485.40 million for the quarter, compared to analyst estimates of $478.23 million. Qiagen had a trailing twelve-month return on equity of 14.08% and a net margin of 17.66%. The company's quarterly revenue was down 22.8% on a year-over-year basis. During the same period last year, the company earned $0.80 EPS. What ETFs hold Qiagen's stock? ETFs with the largest weight of Qiagen (NYSE:QGEN) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), First Trust NYSE Arca Biotechnology Index Fund (FBT), Newday Ocean Health ETF (AHOY), VanEck Biotech ETF (BBH), Franklin Genomic Advancements ETF (HELX), ROBO Global Healthcare Technology and Innovation ETF (HTEC) and WisdomTree BioRevolution Fund (WDNA). What guidance has Qiagen issued on next quarter's earnings? Qiagen updated its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided earnings per share guidance of $2.10- for the period, compared to the consensus EPS estimate of $2.10. The company issued revenue guidance of $2.05B-, compared to the consensus revenue estimate of $2.06 billion. What is Thierry Bernard's approval rating as Qiagen's CEO? 33 employees have rated Qiagen Chief Executive Officer Thierry Bernard on Glassdoor.com. Thierry Bernard has an approval rating of 65% among the company's employees. What other stocks do shareholders of Qiagen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Qiagen investors own include NVIDIA (NVDA), QUALCOMM (QCOM), Gilead Sciences (GILD), Advanced Micro Devices (AMD), PayPal (PYPL), Netflix (NFLX), Pfizer (PFE), Cisco Systems (CSCO), Amgen (AMGN) and Lam Research (LRCX). What is Qiagen's stock symbol? Qiagen trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN." Who are Qiagen's major shareholders? Qiagen's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.36%), FIL Ltd (1.35%), DekaBank Deutsche Girozentrale (1.27%), Perpetual Ltd (1.23%), Arrowstreet Capital Limited Partnership (1.22%) and Wellington Management Group LLP (1.21%). How do I buy shares of Qiagen? Shares of QGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Qiagen's stock price today? One share of QGEN stock can currently be purchased for approximately $44.92. How much money does Qiagen make? Qiagen (NYSE:QGEN) has a market capitalization of $10.23 billion and generates $2.14 billion in revenue each year. The company earns $423.21 million in net income (profit) each year or $1.54 on an earnings per share basis. How many employees does Qiagen have? The company employs 6,178 workers across the globe. How can I contact Qiagen? Qiagen's mailing address is HULSTERWEG 82, VENLO P7, 5912. The official website for the company is www.qiagen.com. The company can be reached via phone at (177) 355-6600, via email at ir@qiagen.com, or via fax at 31-77-355-6658. This page (NYSE:QGEN) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Qiagen Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.